Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 16, Issue 2, 2006, Pages 137-147

  Pessina, A C ^a   Ciccariello, L ^a   Perrone, F ^b   Stoico, V ^b   Gussoni, G ^c   Scotti, A ^c   Muggeo, M ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c Italfarmaco SpA   (Italy)

Author keywords

Clinical trial; Combination treatment; Doxazosin; Hypertension; Impaired glucose metabolism; Type 2 diabetes

Indexed keywords

EID: 33644920665     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2005.04.005     Document Type: Article

References (33)

1. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease - part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990;335:827-38.
2. Hansson L. The benefits of lowering elevated blood pressure: a critical review of studies of cardiovascular morbidity and mortality in hypertension. J Hypertens 1996;14:537-44.
3. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
4. Kannel WB. Hypertension: relationship with other risk factors. Drugs 1986;31(Suppl. 1):1-11.
5. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on Framingham Study. Ann Intern Med 1979;90:85-91.
6. Samuelsson O, Wilhelmsen L, Elmfeldt D, et al. Predictors of cardiovascular morbidity in treated hypertension: results from the primary prevention trial in Goteborg. Sweden. J Hypertens 1985;3:167-76.
7. Wilson PWF, Cupples L, Kannel WB. Is hyperglycaemia associated with cardiovascular disease? The Framingham Study. Am Heart J 1991;2:586-90.
8. Consensus Statement. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1992;15(Suppl. 2):68-74.
9. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
10. Anderson KM, Wilson PWF, Odell PM, Kannel WB. Un updated coronary risk profile. A statement for health professionals. Circulation 1991;83(1):356-62.
11. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317:703-13.
12. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995;49(2):295-320.
13. Neaton JD, Grimm RH, Prineas RJ, et al. For the Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study: final results. J Am Med Assoc 1993;270:713-24.
14. Grimm Jr R, Flack J, Grandits G, Elmer PJ, et al. Long term effects on plasma lipids of diet and drugs to treat hypertension. J Am Med Assoc 1996;275:1549-56.
15. Levy D, Walmsley P, Levenstein M. Principal results of the hypertension and lipid trial (HALT): a multicenter study of doxazosin in patients with hypertension. Am Hearth J 1996;131:996-73.
16. Glanz M, Garber AJ, Manda G, et al. Meta analysis of studies using selective alfal-blockers in patients with hypertension and type 2 diabetes. Int J Clin Pract 2001;55:694-701.
17. Daae LN, Westlie L. A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. Blood Press 1998;7(1):39-45.
18. Castrignano R, D'Angelo A, Pati T, et al. A single-blind study of doxazosin in the treatment of mild-to moderate essential hypertensive patients with concomitant non-insulin-dependent diabetes mellitus. Am Heart J 1988;116:1778-84.
19. Calò L, Davis PA, Cantaro S, et al. Effect of doxazosin in mild to moderate hypertensive patients with insulin-dependent diabetes mellitus. Acta Diabetol 1998;35:96-100.
20. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomised to doxazosin vs chlortalidone. J Am Med Assoc 2000;283:1967-75.
21. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Diuretic versus alfa-blocker as first-step antihypertensive therapy. Final results from the antihypertensive and lipid-lowering treatment to prevent hearth attack trial (ALLHAT). Hypertension 2003;42:239-46.
22. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
23. 1999 World Health Organization - International Society of Hypertension Guidelines for the management of hyper-tension. J Hypertens 1999;17:151-83.
24. The Sixth Report of the Joint National Committee on Prevention, detection, Evaluation and Treatment of High blood Pressure. Arch Int Med 1997;157:2413-46.
25. Ceriello A, Squatrito S, editors. Raccomandazioni per la valutazione e la riduzione del rischio cardiovascolare nel diabete "1999". Il Diabete 1999;11(Suppl. to n.3):1-14.
26. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
27. Zusman RM. The role of alpha 1-blockers in combination therapy for hypertension. Int J Clin Pract 2000;54:36-41.
28. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20:1461-4.
29. Glanz M, Garber AJ, Manda G, et al. Meta-analysis of studies using selective alpha 1-blockers in patients with hypertension and type 2 diabetes. Int J Clin Pract 2001;55:694-701.
30. Black HR, Sollins JS, Garofalo JL. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive med-ications: a randomised, placebo-controlled study. Am J Hypertens 2000;13:468-74.
31. Laakso M, Edelman SV, Brechtel G, et al. Decreased effect of insulin to stimulate skeletal muscle blood-flow in obese man: a novel mechanism for insulin resistance. J Clin Invest 1990;85:1844-52.
32. Andersson P, Johansson J, Berne C, et al. Effects of selective alpha 1 and beta 1 adrenoceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. J Hum Hypertens 1994;8:219-26.
33. Andersson P, Lithell H. Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Am J Hypertens 1996;9:323-33.